Rocket Lab (NASDAQ:RKLB) draws closer scrutiny near $50, and the stock currently trades at $55.05, within reach of that level. A record $3.57 billion backlog plus $4.45 billion in cash adds up to roughly $8.02 billion of contracted revenue and liquidity behind a $34.79 billion company.
Rocket Lab flies the Electron small-lift rocket and the HASTE hypersonic test vehicle, is developing the reusable Neutron medium-lift rocket, and builds spacecraft and components through Space Systems. A pending acquisition of Iridium Communications (NASDAQ:IRDM) would add an operating satellite constellation. Shares sat at $84.16 when first-quarter results landed, then fell after Neutron’s debut was delayed to no earlier than 2027.
Neutron Bookings Signal Launch Demand Is Outrunning SupplyThird-quarter revenue reached $267.83 million, up 72.7% year over year and ahead of the $257.18 million consensus. Backlog jumped 52% sequentially on nearly $1 billion in new launch contracts. Neutron has 16 launches booked at a base price raised to $70 million, with the next open slots in the 2030s. CFO Adam Spice said, “We chose to go for higher ASP and lower volumes.”
Defense work strengthens the moat: a Golden Dome Space Based Interceptor selection alongside Raytheon, an $816 million SDA Tracking Layer contract, and a $397 million Space Force award.
Losses, Dilution and Delays Weigh on SharesThird-quarter GAAP EPS of -$0.12 missed the -$0.0665 consensus, and the net loss grew to $79.68 million. Non-GAAP gross margin was delayed to 38.4% from 41.9%. Funding Iridium required issuing 36.8 million shares, and the stock trades at 47 times trailing sales.
Neutron has was delayed repeatedly. CEO Peter Beck declined to give a launch quarter: “I just don’t want to be continually wrong.” Fiscal 2026 EPS consensus has slipped to -$0.3077 from -$0.2660 90 days ago.
Neutron’s First Flight Decides the Next LegManagement expects adjusted EBITDA to turn positive within about six months of a successful Neutron test flight, so the date of that flight determines the profit timeline. Iridium still awaits final regulatory approvals. Fourth-quarter guidance calls for $270 million to $290 million in revenue alongside an adjusted EBITDA loss of $14 million to $20 million. Tank qualification results and the Iridium close are the next milestones to track.
Analysts See 69% Upside Despite a Lagging YearThe consensus target of $93.10 implies 69.1% upside from current levels and 86.2% from $50. Targets are one data point, and they shift with views. Of 22 analysts:
Rocket Lab is down 21.09% year to date while the S&P 500 gained 7.37%. Over one year, it rose 27.11% against the index’s 9.99%. A beta of 3.176 means swings run large in both directions.
Rocket Lab’s Case Strengthens at $50At $50, the valuation gap to the analyst consensus target grew.
Roughly 32.9% of backlog converts to revenue within 12 months, and the cash pile supports continued Neutron development. Spice described Neutron contracts as carrying “real deposits” and cancellation fees, which makes that backlog firmer than options.
The path higher runs through three drivers over the next 12 to 18 months: the Iridium close, Electron and HASTE execution, and Neutron’s first flight. Each converts the backlog into margin. A further Neutron slip past 2027 or a failed debut would invalidate the thesis.
At $50, the stock would be backed by $8 billion in visible demand and cash for a company whose biggest drivers has yet to fly.